Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Avi Eliahu

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|June 1, 2022
Capsule-Based dry powder inhaler evaluation using CFD-DEM simulations and next generation impactor dataLucilla C Almeida, Rahul Bharadwaj, Avi Eliahu, et al.
Clinical and Translational Science|February 14, 2022
Phase I and scintigraphy studies to evaluate safety, tolerability, pharmacokinetics, and lung deposition of inhaled GDC-0214 in healthy volunteersRui Zhu, Hubert Chen, Joshua Galanter, et al.
The Journal of Allergy and Clinical Immunology|March 21, 2021
Inhaled JAK inhibitor GDC-0214 reduces exhaled nitric oxide in patients with mild asthma: A randomized, controlled, proof-of-activity trialIrene E Braithwaite, Fang Cai, Jennifer A Tom, et al.
Pulmonary Pharmacology & Therapeutics|June 1, 2022
Effects of inhaled JAK inhibitor GDC-4379 on exhaled nitric oxide and peripheral biomarkers of inflammationHubert Chen, Rebecca Kunder, Yixuan Zou, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|June 1, 2022
Capsule-Based dry powder inhaler evaluation using CFD-DEM simulations and next generation impactor dataLucilla C Almeida, Rahul Bharadwaj, Avi Eliahu, et al.
Clinical and Translational Science|February 14, 2022
Phase I and scintigraphy studies to evaluate safety, tolerability, pharmacokinetics, and lung deposition of inhaled GDC-0214 in healthy volunteersRui Zhu, Hubert Chen, Joshua Galanter, et al.
The Journal of Allergy and Clinical Immunology|March 21, 2021
Inhaled JAK inhibitor GDC-0214 reduces exhaled nitric oxide in patients with mild asthma: A randomized, controlled, proof-of-activity trialIrene E Braithwaite, Fang Cai, Jennifer A Tom, et al.
Pulmonary Pharmacology & Therapeutics|June 1, 2022
Effects of inhaled JAK inhibitor GDC-4379 on exhaled nitric oxide and peripheral biomarkers of inflammationHubert Chen, Rebecca Kunder, Yixuan Zou, et al.
Pageof 1